Antiretrovirals
Researchers from Wingate University provide details of new studies and findings in the area of antiretrovirals
Published in AIDS Weekly, May 12th, 2008
According to a study from the United States, "Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was approved by FDA on January 18, 2008, for use in combination with other antiretroviral agents for the treatment of HIM infection in antiretroviral treatment-experienced adult patients who have evidence of viral replication and HIM strains resistant to NNRTIs and other antiretroviral agents. Etravirine has a flexible structure that allows multiple binding configurations, making this agent active against wild-type HIM viral strains and against viral strains with known NNRTI resistance mutations."
"In clinical trials, etravirine has...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-05-12)
More Articles from AIDS Weekly
- Gender Studies
Research conducted at E. Delazzari and co-authors has provided new information about gender studies - HIV/AIDS
Findings from K. Danel and co-authors provide new insights into HIV/AIDS - HIV/AIDS
New HIV/AIDS research has been reported by scientists at INSERM - HIV/AIDS
New HIV/AIDS study findings have been published by W. Manosuthi and colleagues - HIV/AIDS
New research on HIV/AIDS from University of Oviedo summarized - HIV/AIDS
Reports from Centers for Disease Control and Prevention advance knowledge in HIV/AIDS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
